This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
multiple doses of MK-3614 in male participants with mild to moderate hypertension. The
primary hypotheses are: 1) Multiple oral doses of MK-3614 are sufficiently safe and well
tolerated to permit continued clinical investigation 2) Aortic Augmentation Index (Aix) is
reduced 24 hours post the last dose of MK-3614 administered compared to placebo and 3)
Increase in the 12-hour weighted averages (TWA 0-12hours) of the heart rate is within 15
beats per minute (bpm) of baseline on first day of multiple dosing of MK-3614 and within 10
bpm of baseline on last day of multiple dosing of MK-3614.